Valiant Laboratories Q1 FY27 Results

Consolidated Revenue from Operations: ₹115.29 crore (₹11,528.51 lakh)
Consolidated Net Profit: ₹21.10 crore (₹2,110.30 lakh)

Reader Takeaway: Subsidiary's strong contribution boosts consolidated profits; monitor integration and future earnings.

What just happened

Valiant Laboratories Ltd. has announced its financial results for the first quarter of the fiscal year 2027 (Q1 FY27), ending June 30, 2026. The company reported consolidated revenue from operations of ₹115.29 crore and a consolidated net profit of ₹21.10 crore. The basic Earnings Per Share (EPS) stood at ₹3.89.

Why this matters

The consolidated figures, which include the performance of its subsidiary Valiant Advanced Sciences Private Limited, show a significant uplift compared to the standalone results. This highlights the material impact of the subsidiary on the company's overall financial health and profitability. Investors get a more comprehensive view of the group's performance.

The backstory

This is the first reported quarter where Valiant Laboratories has presented consolidated financial results that prominently feature the contribution of Valiant Advanced Sciences Private Limited. The Board of Directors approved these results on August 10, 2026.

What changes now

Investors will now analyze the integrated performance of Valiant Laboratories and its subsidiary. The focus shifts to understanding the operational synergies and future growth potential arising from this combined entity. Future reporting will likely continue with consolidated figures, providing a clearer picture of the group's economic footprint.

Risks to watch

The auditor's report mentioned reliance on audit reports from other auditors for the subsidiary. While standard practice, it's a point for investors to consider regarding audit transparency and the depth of independent verification of the subsidiary's financials.

Peer comparison

(Peer comparison data not available in the filing.)

Context metrics (time-bound)

• Consolidated Revenue (Q1 FY27): ₹115.29 crore
• Standalone Revenue (Q1 FY27): ₹73.42 crore
• Consolidated Net Profit (Q1 FY27): ₹21.10 crore
• Standalone Net Profit (Q1 FY27): ₹9.48 crore
• Consolidated Basic EPS (Q1 FY27): ₹3.89
• Standalone Basic EPS (Q1 FY27): ₹1.75

What to track next

Investors should monitor subsequent quarterly results to assess the sustainability of the higher consolidated profits and revenue. Tracking announcements related to operational integration and any strategic developments concerning Valiant Advanced Sciences Private Limited will also be crucial.